Lyra Therapeutics announced the appointment of Harlan W. Waksal MD, as Executive Chairman. Dr. Waksal most recently served as President, Chief Executive Officer and Member of the Board of Directors of Kadmon Holdings prior to its acquisition by Sanofi in November 2021. With more than 30 years of scientific, clinical development, business development and management experience in the industry, Dr. Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3335 USD | +2.46% | -6.16% | -93.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-93.64% | 19.84M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- LYRA Stock
- News Lyra Therapeutics, Inc.
- Lyra Therapeutics Appoints Harlan W. Waksal as Executive Chairman